CeriBell (NASDAQ:CBLL) Receives Consensus Rating of “Buy” from Brokerages

CeriBell (NASDAQ:CBLL) has been given a consensus recommendation of “Buy” by the seven research firms that are covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year is $32.50.

Several equities analysts have weighed in on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on CeriBell in a report on Friday, April 4th. They set a “buy” rating and a $32.00 price target on the stock.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $11.15 on Friday. The company’s fifty day moving average is $21.20. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. On average, research analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC acquired a new stake in CeriBell during the fourth quarter valued at $128,120,000. TPG GP A LLC bought a new stake in shares of CeriBell in the 4th quarter valued at approximately $102,677,000. Red Tree Management LLC bought a new stake in shares of CeriBell in the 4th quarter valued at approximately $57,083,000. Yu Fan acquired a new position in CeriBell in the fourth quarter worth approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new stake in CeriBell in the fourth quarter valued at approximately $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.